Stephen Saad, Group Chief Executive, Aspen
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Address: PO Box 781247
Sandton 2146
Gauteng,South Africa
Tel: +27 11 883 5630
Founded in 1906, Norgine is a specialty pharmaceutical company with an extensive pan-European presence. Throughout our long history, we have sought to develop and market high quality, innovative products for the benefit of both patients and physicians. We are committed to developing products not only to treat life-threatening conditions, but importantly, to improve the quality of life for patients with a variety of acute and chronic illnesses. We have a long-standing tradition of building high quality relationships based on the highest standards, with patients, physicians, employees, partners and other key stakeholders.
In the last fifteen years, we have focused on expanding our pan-European infrastructure, and have moved to strengthen the Research & Development base of the company.
In addition to developing, manufacturing and marketing our own pharmaceutical products, Norgine is an ideal partner for companies seeking assistance in the development and commercialisation of innovative pharmaceutical products across Europe. We value our development partnerships as, together with our own in-house product development, they support our growth ambitions and will help to facilitate our continued business expansion.
We have the resources to bring products to market on a pan-European or single country basis by combining sales and marketing expertise with all development, clinical research, product registration or manufacturing resources that our partners require.
In the years ahead, Norgine will continue to implement this successful strategy, building on our established infrastructure, strengthening our pan-European presence and collaborating with like-minded companies and organisations. By consolidating our successes, we can ensure we meet the challenges of an exciting future.
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It is a purely romantic…
Your professional career went back and forth between creating your own business and running a smaller and very dynamic structure and managing over a thousand of employees for multinational organizations.…
You were recently appointed at the head of Eli Lilly South African operations. What is the specific mission you have been given? Eli Lilly South Africa is in an interesting…
Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes…
An emerging country with a dynamic market, South Africa is widely seen as the gateway to Africa. From major multinational pharmaceutical corporations to burgeoning local generic companies, a wide…
We interviewed Graham Somerville in 2004, the year when IHD, formerly jointly owned by 11 major pharmaceutical companies, was acquired by UTi. We are interviewing you today at the head…
Dr Pillay, South Africa recently became a member of BRICS. With this distinction, we need to improve our healthcare outcomes relative to other BRICS countries. All countries have challenges with…
The South African affiliate was established in June 2003. Could you come back on the main milestones in the company’s development from 2003 onwards? Yamanouchi as an entity was an…
Since we that came to South Africa in 2005 and interviewed you, what have been the main changes both in the market place, and within Sanofi as an organization? The…
In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new…
Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio?…
See our Cookie Privacy Policy Here
